Počet záznamů: 1
Future use of mitocans against tumour-initiating cells?
- 1.
SYSNO ASEP 0325050 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Future use of mitocans against tumour-initiating cells? Tvůrce(i) Morrison, B.J. (AU)
Anděra, Ladislav (UMG-J) RID
Reynolds, B.A. (AU)
Ralph, S.J. (AU)
Neužil, Jiří (BTO-N) RIDCelkový počet autorů 5 Zdroj.dok. Molecular Nutrition & Food Research. - : Wiley - ISSN 1613-4125
Roč. 53, č. 1 (2009), s. 147-153Poč.str. 7 s. Jazyk dok. eng - angličtina Země vyd. DE - Německo Klíč. slova mitocans ; tumour-initiating cells ; metastasis Vědní obor RIV EB - Genetika a molekulární biologie CEZ AV0Z50520514 - UMG-J (2005-2011) AV0Z50520701 - BTO-N (2007-2013) UT WOS 000262869400013 DOI 10.1002/mnfr.200800254 Anotace Tumour heterogeneity has several important consequences including making their classification by morphological and genetic analysis more difficult because of the diversity of cells, failing to eliminate one of the cell subtypes and differing abilities of the cell subtypes for dissemination and metastasis. Recently, a rare subpopulation of cells within tumours has been described with the ability to initiate and sustain tumour growth, to resist traditional therapies and to allow for secondary tumour dissemination. These cells are termed tumour-initiating cells (TICs). Understanding tumour heterogeneity will be critical for advancing treatments for cancer that target TIC subpopulations of cells in a tumour able to resist traditional treatments and eliminate them before metastatic disease occurs. Therefore, knowledge of the molecular mechanism(s) of resistance of TICs to treatment and overcoming it will be essential in order to develop effective drug strategies for cancer therapy. Pracoviště Ústav molekulární genetiky Kontakt Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Rok sběru 2010
Počet záznamů: 1